In Q2 2026, Stryker Corporation delivered a 9.4% increase in net sales and expanded adjusted operating margins by 170 basis points, reflecting sustained demand for its diversified product portfolio and accelerated adoption of its Mako robotic surgical system. MedSurg & Neurotechnology segment drove much of the growth, while Orthopaedics remained resilient amid ongoing innovation and service integration. The company’s strong global patent portfolio and regulatory expertise underpin its competitive moat versus peers like Zimmer Biomet and Intuitive Surgical. Key risks include regulatory complexities, supply chain pressures, and competitive pricing headwinds. Capitalized by strong liquidity and low leverage, Stryker is positioned to leverage emerging market penetration and continued R&D investment toward expanding market share and improving clinical outcomes.